Please try another search
Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; ICOone single-dose disposable dry powder inhaler; and ICOone nasal single-dose dry powder inhaler now for nasal use. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius to develop dry powder inhalation product, as well as collaboration with Monash h University to. to develop an inhalable and preventive oxytocin treatment to provide effective protection against cotries. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Mats Johansson | 61 | 2013 | Director |
Berndt Axelsson | 63 | 2013 | Independent Director |
Rikard Roos | 49 | - | Member of Business Advisory Board |
Sven Totté | 53 | 2017 | Independent Director |
Gunnar Gardemyr | 63 | 2020 | Independent Chairman of the Board |
Lennart Holm | 63 | - | Member of Business Advisory Board |
Kjell Larsson | - | - | Member of Scientific Advisory Board |
Björn Andersson | - | - | Member of Business Advisory Board |
Orest Lastow | 59 | 2013 | Co-Founder, CTO, Innovation Lead & Director |
Carl Lindgren | 55 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review